Transplanting a patient’s own healthy skin to treat their skin ulcers was found to be safe and effective for three…
Articles by José Lopes, PhD
A compound called rigosertib effectively suppressed tumor growth and induced selective death of cancer cells both in patient-derived cells and…
A provisional diagnosis based on clinical information is more accurate than imaging of skin biopsies in newborns and infants with…
Increased levels of a protein called decorin extended survival, reduced skin fibrosis (scarring) and delayed the development of paw deformities…
Diagnostic testing in patients with epidermolysis bullosa (EB) is more frequent in the most severe disease types, according to…
Abeona Therapeutics plans to start a Phase 3 trial in 2019 testing the cell therapy candidate EB-101 as…
A 1% diacerein ointment could be a safe and well-tolerated way to treat generalized severe epidermolysis bullosa simplex (EBS), according to…
Treatment with intravenous immunoglobulin (IVIG) and off-label rituximab can lead to complete remission of epidermolysis bullosa acquisita (EBA), according to a…
Treatment with a wound care ointment called Terrasil reduced pain, itching, and blistering in the wound area in a…
Treatment targeting a specific molecule involved in inflammation — called PI3K-delta — eased skin lesions and prevented blistering in mouse…
An enzyme called granzyme B (GzmB) may be a key mediator of blistering in patients with epidermolysis bullosa acquisita…
A Phase 1/2 clinical trial assessing investigational QR-313 as a treatment for dystrophic epidermolysis bullosa (DEB) has begun and is now…